-- 取締役のムニッシュ・ナンダ氏は、2026年5月1日にCeco Environmental（CECO）の株式11,218株を830,145ドルで売却しました。SECへのフォーム4の提出後、ナンダ氏は同社の普通株式合計62,031株を保有しており、そのうち62,031株は直接保有しています。 SEC提出書類：https://www.sec.gov/Archives/edgar/data/3197/000119312526203739/xslF345X05/ownership.xml
Price: $77.31, Change: $+3.01, Percent Change: +4.05%
Lattice Semiconductor (LSCC) agreed to acquire AMI, a cloud and AI-server management software company, for $1.65 billion in cash and stock from THL Partners.The purchase includes $1 billion in cash and $650 million in Lattice stock. The acquisition is expected to close in Q3, subject to regulatory approvals and other conditions, Lattice said Monday in a statement.The transaction is expected to be accretive to gross margin, free cash flow and earnings per share on an adjusted basis, and AMI is projected to generate more than $200 million in revenue in 2026, Lattice said.Lattice shares rose 0.4% in after-hours trading after gaining 3.8% in the regular session.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Vertex delivered mixed Q1 results with revenue of $2.99B (+8% Y/Y) falling $10M short of expectations, though non-GAAP EPS of $4.47 (+10% Y/Y) beat the consensus by $0.16. The quarter demonstrated successful execution of VRTX's multi-product launch strategy, with ALYFTREK generating $424.4M (vs. $53.9M prior year), CASGEVY contributing $42.9M (+202% Y/Y), and JOURNAVX adding $29.0M in its second commercialization year. Recent FDA label extensions for ALYFTREK and TRIKAFTA expanded CF patient eligibility to ~95% in the U.S., adding roughly 800 more patients. VRTX maintained its 2026 guidance unchanged with total revenue expectations of $12.95B-$13.1B and non-CF product revenue of $500M or greater. We view the operating leverage positively, with revenue growth outpacing expense increases, and believe the diversification strategy beyond CF continues to gain traction with meaningful contributions from newly launched therapies across multiple therapeutic areas.